Laurus Labs: Anti-retroviral business disappoints but synthesis-led growth intact

Laurus Labs: Anti-retroviral business disappoints but synthesis-led growth intact Capex execution will be key to the companyâ€™s growth prospects; diversification initiatives should be supportive